为何资本敢砸下近20亿真金白银？深扒资本重仓的早筛成长股Mirxes

Group 1 - Mirxes has officially announced a new share placement, expected to raise approximately HKD 700 million, bringing total fundraising to nearly HKD 2 billion within just eight months [1] - The company has demonstrated strong execution capabilities, meeting key milestones in product registration and commercial partnerships, which has instilled confidence in investors [2] - Mirxes operates in the "in vitro diagnostics (IVD)" sector, offering a clear business model with significant user demand, allowing for predictable growth and cash flow visibility [3] Group 2 - Mirxes is the only company with domestic approval for early cancer screening products, establishing a competitive advantage in technology, market positioning, and brand recognition [4] - The company is pursuing multiple cancer types, ensuring both short-term performance and long-term growth potential through a combination strategy of deep breakthroughs in single cancer types and broad coverage of multiple cancers [4] - Mirxes has built a significant real-world database of cancer screening data in Asia, which serves as a foundation for future collaborations and integrated diagnostic solutions [4] Group 3 - The company has a clear development roadmap, with significant progress expected in colorectal cancer pipelines and ongoing projects for single and multiple cancer screenings [5] - A strategic partnership with Crystal Technology aims to leverage Mirxes' cancer screening data with AI capabilities, transitioning from mere testing to providing data insights and potential intervention targets [6][7] - The global trend towards multi-cancer screening being included in insurance coverage is creating a favorable market environment for Mirxes, positioning it as a leader ready to capitalize on this demand [8]